• Cytavis BioPharma GmbH, of Hamburg, Germany, reported that its melanoma candidate, Aviscumine (CY503), may improve survival of patients with refractory stage IV metastatic melanoma. In the Phase II open-label trial, 31 eligible patients with unresectable metastatic melanoma, who had previously failed antineoplastic therapy, received subcutaneous injections of Aviscumine. Three-month progression-free survival was 32.3 percent, and median overall survival was 11 months.

• Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., reported results from a Phase IIb (MOBILITY) trial of sarilumab in rheumatoid arthritis and ankylosing spondylitis. The trial showed patients treated with sarilumab in combination with methotrexate achieved a significant improvement in symptoms. Secondary endpoints including ACR 50, ACR 70 and DAS 28 also showed improvement.

• Thallion Pharmaceuticals Inc., of Montreal, suspended enrollment in its high-dose cohort of the Phase II SHIGATEC trial due to a product-out-of-specification finding during routine stability testing of its anti-Stx1 antibody. The company will analyze the problem and report the findings of its assessment. As a result of the analysis, the study may be continued or suspended until new clinical material is manufactured. Thallion stock (TSE:TLN) fell 14.3 percent, or C3 cents, to close at C15 cents Wednesday.

No Comments